SCHEMBL23212032

SCHEMBL23212032

CC(c1ccc(C(F)(F)F)cc1)C1CCN(C(=O)O)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD1 P28347 3/20 0.50
DPP4 P27487 2/20 0.50
DPP7 Q9UHL4 2/20 0.50
DPP8 Q6V1X1 1/20 0.50
EPHX2 P34913 6/20 0.45
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MMP1 P03956 1/20 0.42
MMP13 P45452 1/20 0.42
AKR1C3 P42330 2/20 0.41
AKR1C2 P52895 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ADAMTS7 Q9UKP4 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
NOTUM Q6P988 1/20 0.41
CACNA1A O00555 1/20 0.41
CACNA2D1 P54289 1/20 0.41
CACNA1B Q00975 1/20 0.41
CACNB1 Q02641 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211870 0.86 DPP4 (0.46) TEAD1DPP4DPP7DPP8EPHX2
SCHEMBL23211926 0.83 MMP13 (0.54) TEAD1DPP4MMP13
SCHEMBL28162309 0.83 RPS6KB1 (0.53) TEAD1DPP4DPP7DPP8EPHX2
SCHEMBL27779319 0.81 EPHX2 (0.40) DPP4DPP7DPP8EPHX2
SCHEMBL28390751 0.80 DPP4 (0.45) TEAD1DPP4DPP7DPP8EPHX2
SCHEMBL23212023 0.77 TEAD1 (0.41) TEAD1DPP4DPP7DPP8AKR1C3
SCHEMBL21381906 0.75 GAA (0.48) TEAD1DPP4DPP7EPHX2GAA
SCHEMBL2636716 0.75 LIPE (0.52) GAATDP1NOTUM
SCHEMBL17942511 0.75 ADAMTS7 (0.45) EPHX2GAATDP1MMP1MMP13
SCHEMBL30567836 0.73 MGLL (0.45) TEAD1DPP4DPP7DPP8AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC TEAD1 3866/4885DPP4 542/4885DPP7 730/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC TEAD1 3866/4885DPP4 542/4885DPP7 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.